改善HCC治疗:创新地将HDAC2抑制剂与PD-1/PD-L1抑制剂结合起来

Rui Han1,2,3,4,5,6, Changquan Ling7,8, Yuqian Wang7,8

  • 1Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, P. R. China. dianxiqiao@foxmail.com.

Cancer cell international
|September 16, 2023
PubMed
概括

这项研究探讨了将基因组脱乙酶2抑制剂与免疫检查点抑制剂结合起来,用于肝细胞癌治疗. 这种新的方法可能会改善HCC患者的抗癌免疫力和治疗疗效.

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K